Skip to main content

1 Result(s)

within Hitoshi Inagaki Remove this filter Cancer Research Remove this filter

and

  1. No Access

    Article

    A study of second-line irinotecan plus cisplatin vs. irinotecan alone in platinum-naïve patients with early relapse of gastric cancer refractory to adjuvant S-1 monotherapy: exploratory subgroup analysis of the randomized phase III TRICS trial

    Many patients with gastric cancer relapse during or early after adjuvant chemotherapy. The standard treatment for early relapse patients is a second-line chemotherapy (SLC) based on irinotecan, taxanes, or a p...

    Kazuhiro Nishikawa, Kenta Murotani… in Cancer Chemotherapy and Pharmacology (2019)